US FDA generics chief moves to new role
This article was originally published in Scrip
Gary Buehler, who has been the head of the US Food and Drug Administration’s Office of Generic Drugs for nearly a decade, is moving to a new role within the agency. In his new position, Mr Buehler will play a key role in negotiations and activities relating to generic drug user fees.
You may also be interested in...
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.